Results from early clinical trials suggest that liraglutide, a GLP-1 drugs, may help protect the brain against cognitive ...

The availability of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as liraglutide and semaglutide, and a GLP-1 ...

Though GLP-1R receptor agonist drugs work well on their own, they may work better when paired with the right lifestyle ...

We are at an inflection point regarding treatment of obesity,” said Robert Kushner, MD, MS, Northwestern University Feinberg ...

I think the current obesity specialty pharmacy market provides particularly interesting lessons for businesses in a rapidly ...

ELAD is one of several trials looking at whether GLP-1 drugs can benefit neurodegenerative diseases. In two phase III studies ...

WEIGHT-loss injections could help people quit smoking, a study suggests. It’s one of many benefits to have come out of the ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce secondary stroke risk by 16% among stroke survivors with diabetes or obesity.

Ozempic, Wegovy and other GLP-1 medications have gained widespread popularity for weight loss and diabetes control in recent years — but the spike in demand has made it difficult for some people ...

“We’ve known for some time through animal work that GLP-1 has a different type of activity in the brain,” said Dr. Maria Carrillo, chief science officer and medical affairs lead for the ...

Ozempic, initially developed for managing type 2 diabetes, has gained significant attention as a weight loss medication in ...

With promising Phase II data in hand, Viking Therapeutics is pushing its subcutaneous GLP-1/GIP receptor dual agonist into ...